← Eichor
Study identifier: NCT06745882 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Condition: Non-small Cell Lung Cancer  ·  Sponsor: H. Lee Moffitt Cancer Center and Research Institute

PhasePhase 2
Planned participants318
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age, ECOG performance status 0-2, and may have detectable ctDNA at baseline.

This description comes directly from the study's public registry record.

Talk to the study team

Anahid Aminpour  ·  813-745-0287  ·  anahid.aminpour@moffitt.org

Always discuss trial participation with your own doctor first.

Locations (6)

Moffitt Cancer CenterTampa, Florida, United StatesRecruiting
Johns Hopkins Sidney Kimmel Comprehensive Cancer CenterBaltimore, Maryland, United StatesRecruiting
TidalHealth Peninsula RegionalSalisbury, Maryland, United StatesRecruiting
Montefiore Medical Cancer CenterThe Bronx, New York, United StatesRecruiting
Baptist Clinical Research InstituteMemphis, Tennessee, United StatesRecruiting
Nashville General HospitalNashville, Tennessee, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06745882